About Moleculin Biotech, Inc. (adapted from Moleculin Biotech, Inc. prospectus):
They are a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, which they refer to as MD Anderson.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.